WebApr 12, 2024 · However, Pear Therapeutics' recent bankruptcy, a pioneer in the field of prescription digital therapeutics (PDTs), has brought up some serious issues regarding ... reSET-O, and Somryst, which ... WebApr 10, 2024 · The US-based firm Pear Therapeutics, a company focused on developing and commercialising software-based medicine, has filed for Chapter 11 bankruptcy as it …
Did you know?
WebApr 14, 2024 · Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) major shareholder 5Am Partners Iv, Llc sold 16,544,113 shares of the business’s stock in a transaction that … WebJan 18, 2024 · BOSTON, Jan. 18, 2024, Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital …
WebFeb 27, 2024 · Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. WebJun 7, 2024 · UDI Codes: reSET Mobile App, iOS (01) 10851580008088 (10) 1 reSET Mobile App, Android (01) 10851580008095 (10) 1 : Recalling Firm/ Manufacturer: Pear Therapeutics, Inc. 201 Mission St Ste 1450 San Francisco CA 94105-1882: For Additional Information Contact: Jamie Nesbitt 415-349-5171
WebJun 22, 2024 · Pear Therapeutics, which has three FDA-authorized apps to treat psychiatric disorders, plans to go public in a $1.6 billion special purpose acquisition corporation, or … WebPear Therapeutics is not accepting new prescriptions for its products, reSET ®, reSET-O ®, and Somryst ®, nor will refills be dispensed at this time. We will attempt to keep our products available for patients who are already using the products for the duration of the current fill of their prescription, but there can be no assurance that we ...
WebApr 10, 2024 · The US-based firm Pear Therapeutics, a company focused on developing and commercialising software-based medicine, has filed for Chapter 11 bankruptcy as it struggled to get insurers to pay for its technology and laid off 92 per cent of its workforce, or about 170 employees. In a filing with the US Securities and Exchange Commission (SEC), …
WebApr 12, 2024 · 近日，上市仅一年多的美国数字疗法明星企业Pear Therapeutics（以下简称“Pear”）宣布，已申请破产保护，并正在寻求出售其业务与资产。. 根据公开资料，2024年12月，Pear通过SPAC形式上市，交易价值16亿美元，约合人民币110亿，被称为“数字疗法第一股”，并创下 ... ft magazineWebApr 12, 2024 · 后来Pear更是搭上了诺华的快车。reSET™上市不久后（2024年），Pear接到了诺华的订单，并以此为契机，迅速通过自建和BD“两条腿”，将其被验证的 ... ft lei árfolyamWebAug 2, 2024 · Pear Therapeutics' reSET-O, a prescription app for treating opioid use disorder, may lower patients’ health care costs, compared with patients who don’t use the app, according to a study published in the journal Hospital Practice. “Engagement and continued treatment with reSET-O in patients with OUD treated with buprenorphine is associated … ft magazinWebMar 17, 2024 · Pear’s product, reSET ®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O ®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. ft magazine feedbackWebApr 12, 2024 · The prices of reSET and reSET-O are often quoted to be north of $1,000 and given that they are intended to be used as an adjunct to other outpatient treatment, … ft mba rank 2022WebFeb 23, 2024 · BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Pear Therapeutics, Inc., today announced publication of new analysis demonstrating the cost-effectiveness of reSET-O ®, the first and only FDA-authorized ... ft lej árfolyamWebNov 5, 2024 · Pear's reSET-O for opioid use disorder saves payers $2,150 per patient, real-world claims review finds The study, backed by the digital therapeutics company, measured the change in clinical encounter frequency among opioid use disorder patients who were also prescribed buprenorphine. By Dave Muoio November 05, 2024 01:55 pm Share ft mcclellan gym